new_banner

news

Brigatinib Aniline Intermediate CAS 761440-75-9: A Key Piperazine-Piperidine Building Block

The synthesis of complex kinase inhibitors often requires the assembly of several distinct molecular fragments. In Brigatinib, an important structural component is a substituted aniline bearing a methoxy group and a nitrogen-rich piperidine-piperazine side chain.

2-Methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)aniline (CAS 761440-75-9) provides this structural fragment and is identified in patent and supplier literature as a Brigatinib intermediate.

Chemical Identity and Basic Data

The molecule contains an aromatic aniline core connected to a substituted piperidine ring, which in turn carries a methylpiperazine group.

  • · Product Name: 2-Methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)aniline
  • · CAS Number: 761440-75-9
  • · Molecular Formula: C₁₇H₂₈N₄O
  • · Molecular Weight: 304.43 g/mol
  • · Synonyms: Brigatinib aniline intermediate; 2-Methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]aniline; AP26113 intermediate 4
  • · Typical Purity: 98% as listed in the supplied product specification

PubChem confirms the molecular formula and molecular weight, while patent and chemical-reference sources identify its use as a Brigatinib intermediate.

Structural Features That Define Its Role

The compound combines three important structural elements.

Methoxy-substituted aniline: The aromatic amino group provides a reactive site for subsequent bond formation, while the methoxy substituent forms part of the final substitution pattern.

Piperidine ring: This saturated six-membered nitrogen heterocycle links the aromatic portion to the terminal nitrogen-containing group.

N-Methylpiperazine: The piperazine substituent contributes additional nitrogen atoms and forms an important part of the side-chain architecture.

The combination creates a relatively complex building block that can be incorporated into later stages of kinase inhibitor synthesis.

Its Position in Brigatinib Synthesis

Brigatinib is an ALK and ROS1 tyrosine kinase inhibitor used in the treatment of certain patients with ALK-positive non-small cell lung cancer.

The aniline intermediate CAS 761440-75-9 supplies one of the two major structural fragments used in the final assembly of Brigatinib.

Patent literature describes routes to this intermediate through construction of the substituted piperidine-piperazine side chain, followed by conversion of the aromatic nitro group into the required amino functionality.

In a later synthetic stage, the aniline functionality can participate in coupling with an appropriately substituted pyrimidine-containing fragment.

This makes the compound an advanced pharmaceutical building block rather than a simple aromatic amine.

Why Process Consistency Is Important

The molecule contains multiple nitrogen atoms and several structurally similar ring environments. This can make impurity control important during synthesis and purification.

Potential quality concerns include:

  • · Incomplete formation of the piperazine-piperidine side chain
  • · Residual nitro-containing precursor
  • · Unreacted aromatic starting materials
  • · Related piperidine or piperazine impurities
  • · Residual solvents and inorganic impurities

For downstream pharmaceutical synthesis, the amine functionality and overall impurity profile should be evaluated together.

Recommended Procurement and Analytical Checks

Before selecting a supplier, pharmaceutical buyers should review:

Identity: Confirm CAS 761440-75-9, molecular formula, and molecular weight.

Assay: Verify chromatographic purity and the analytical method used.

Related substances: Assess structurally related amine and heterocyclic impurities.

Residual solvents: Request relevant residual-solvent information.

Batch consistency: Compare analytical profiles between different production batches.

A batch-specific Certificate of Analysis is particularly important when the compound will be used in a multi-step pharmaceutical manufacturing route.

SHLZ Pharma: Pharmaceutical Intermediate Customization

SHLZ Pharma provides R&D, customization, and production services for pharmaceutical intermediates and APIs.

Its company profile describes laboratory development, pilot production, and larger-scale manufacturing infrastructure. The company reports experience with multiple reaction types and engineering scale-up, supporting projects from early development through larger production requirements.

For customers sourcing Brigatinib-related building blocks, these capabilities can be relevant when discussing specifications, analytical control, and production planning.

Conclusion

2-Methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)aniline (CAS 761440-75-9) is an advanced aniline building block associated with Brigatinib synthesis.

Its molecular formula is C₁₇H₂₈N₄O, with a molecular weight of 304.43 g/mol. The compound combines a methoxy-substituted aromatic amine with a piperidine-piperazine side chain, making it an important structural component in pharmaceutical intermediate chemistry.

For B2B procurement, buyers should prioritize chemical identity, assay, related-substance control, residual solvents, and batch consistency.


Post time: Nov-13-2026